Pharming Group NV (OTCMKTS:PHGUF) Short Interest Up 98.5% in July

Key Points

• Pharming Group NV experienced a significant increase in short interest, rising by 98.5% from mid-July to July 31st, totaling 4,952,300 shares.
• The company's stock price remained flat at $1.16, with a 12-month low of $0.75 and a high of $1.19.
• Pharming Group develops therapies for rare diseases and offers RUCONEST for hereditary angioedema and Joenja for activated PI3K delta syndrome.

Pharming Group NV (OTCMKTS:PHGUF - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 4,952,300 shares, anincreaseof98.5% from the July 15th total of 2,494,900 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. Currently,0.7% of the shares of the stock are sold short. Currently,0.7% of the shares of the stock are sold short. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Pharming Group Stock Performance

PHGUF stock traded up $0.14 on Friday, hitting $1.30. 300 shares of the company's stock traded hands, compared to its average volume of 500. Pharming Group has a 1-year low of $0.7450 and a 1-year high of $1.30. The stock has a fifty day moving average of $1.15 and a 200-day moving average of $1.01. The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.51.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.